Tilray Brands, Inc. (TLRY): what the price assumes

boothcheck covers Tilray Brands, Inc. (TLRY) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TLRY

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The price sits below what even a 5%/yr revenue decline would warrant; the inversion reports a bound, not a solved growth path.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11% cost of capital with 4% terminal growth over a 5-year stage, holding a 13.2% terminal operating margin (33.1% gross margin x the 40% mature-conversion prior).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=2)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Tilray is four businesses in one wrapper, beverage, cannabis, distribution, and wellness, and the operating tape just turned: record fiscal third-quarter net revenue of $206.7 million with 11% organic growth and a net loss narrowed to $25.2 million from $793.5 million a year earlier.
• The capital-allocation record is the specific risk: the FY2025 10-K's own goodwill assessment wrote the beverage segment's goodwill down to nil, and the company continues to issue shares through a $180 million at-the-market program and debt-for-equity exchanges.
• Fiscal fourth-quarter and full-year results land in late July 2026 against reconfirmed FY2026 (ending May 31, 2026) adjusted EBITDA guidance of $62 to $72 million; hitting it would mark the first clean, impairment-free year of the new configuration.

Bull Case

The market is pricing Tilray for decay it is not currently experiencing. At about 0.8x revenue, the price sits below what even a business shrinking sales 5% a year would warrant, and the stock trades at roughly 0.3x its $14.10 book value per share. Set that against the actual direction of the fundamentals: fiscal third-quarter net revenue hit a record $206.7 million, up 11% year over year with 11% organic growth, gross profit expanded 6% to $55 million, and the net loss shrank to $25.2 million from $793.5 million, a comparison flattered by prior-year impairments but real underneath, since the current quarter carried zero impairment charges. A price calibrated for decline paired with a business posting record revenue is the basic asymmetry here.

The growth engine is increasingly international. The FY2025 10-K reports international cannabis net revenue rising 19% on a constant-currency basis to $63.2 million, and describes the Canadian production base as "some of the highest-quality, lowest cost cannabis production operations in Canada, with the scale and distribution network that differentiates us from our competitors in the industry". The wellness arm keeps extending its Whole Foods-partnered branded product line per the filing, and the beverage strategy has shifted from acquiring to integrating, with the 10-K describing a focus on integrating the acquired craft brands and improving cost structure. Management reconfirmed FY2026 adjusted EBITDA guidance of $62 to $72 million, growth of 13% to 31% over fiscal 2025.

The balance sheet is the quiet strength that lets the turnaround breathe. Debt stands at just 0.01x equity after the write-downs and ongoing note retirements, the current ratio is 2.79, and the company has been swapping convertible debt for stock ahead of the June 2027 maturity. Whatever one thinks of the dilution, the result is a company with minimal leverage, positive gross margin momentum, and four revenue streams, priced below its net book value. For a speculative-stage story, the downside is unusually asset-backed, and the upside needs only the operating line to keep doing what it did last quarter.

Bear Case

Judge management by where the capital went. Tilray assembled its four-segment empire through years of stock-funded acquisitions, and the accounting has now rendered its verdict on much of that spending: fiscal 2025 closed with a $1.3969 billion non-cash impairment tied to the 2021 Aphria combination, and the FY2025 10-K's own goodwill assessment, using a 12.25% discount rate and 7% average revenue growth, brought the remaining beverage goodwill balance to nil. Goodwill at zero is the balance sheet saying the craft-beverage acquisition spree, at the prices paid, created no lasting value. The December 2, 2025 reverse stock split that retroactively restated the share count was the cosmetic end of that era, undertaken after the stock had spent months fighting Nasdaq's minimum bid requirement.

The equity is still being used as the company's checkbook. A $180 million at-the-market program stands ready with Jefferies, TD Securities, and Roth, and between June 15 and June 24, 2026 alone, Tilray issued 2,638,341 shares to retire $12 million of its 5.20% convertible notes due June 2027. Each exchange strengthens the balance sheet by handing new paper to noteholders, a rational maneuver that nonetheless transfers value away from existing holders a slice at a time, on a market value of only $497 million where each issuance is material.

And the operations, for all the record-revenue headlines, still do not generate cash. Operating cash flow was negative over the trailing year, free cash flow was negative in all four quarters, and the composite bankruptcy-risk score sits deep in the distress zone even with minimal debt, dragged by accumulated deficits. The profitability guidance is a company-adjusted EBITDA figure of $62 to $72 million; the GAAP operating line remains a loss, and the 10-K concedes the craft-beer market it diversified into carries strong, consolidating competition. The bear case is not that Tilray fails suddenly. It is that the business keeps treading water at breakeven-adjusted profitability while the share count quietly grows, and cheap keeps getting cheaper per share even if the enterprise never shrinks.

Valuation

Because the operating line is not yet normally profitable, the price reads off sales, and the reading is stark: at about 0.8x revenue, the price sits below what even a 5% annual revenue decline would support, holding an assumed steady-state operating margin of about 13.2%, derived from the 33.1% gross margin rather than anything the income statement has demonstrated. Two trailing operating bases circulate for this company and they should not be conflated: the trailing GAAP figures absorb the fiscal-2025 impairment charges and show deep losses, while the normalized operating record the inversion works from is modestly positive. The trailing year, in other words, describes the write-off of the past, not the run-rate of the present.

The methods split value-versus-growth in the unusual direction. The asset-based frame supports the price with room to spare, reading $4.41 (July 11, 2026) at roughly 0.3x what it would pay, consistent with the stock trading at less than a third of its $14.10 book value; the earnings-based value frames read similarly supportive on the normalized record. Only the growth-crediting methods call the price expensive, at about 1.5x what they support, because projecting the recent low growth forward at a 13.3% cost of capital leaves little room. That pattern is a value-or-trap setup, not a growth bet: the price is defensible on assets today and depends on the turnaround for everything beyond that.

Solvency is two-sided in an instructive way. Conventional leverage is negligible at 0.01x equity with a 2.79 current ratio, and the company has been retiring its 5.20% convertible notes due June 2027 via share exchanges; but the operation itself consumed cash in every quarter of the trailing year, so the turnaround is being financed by the balance sheet and the ATM rather than by the business. The decisive line is management's reconfirmed FY2026 adjusted EBITDA guidance of $62 to $72 million: delivery would begin converting the sales multiple's held margin assumption into demonstrated fact, and a miss would leave the price resting on book value alone.

Catalysts

The fiscal year ended May 31, 2026, and fourth-quarter plus full-year results are expected in late July 2026, with aggregator calendars pointing to July 27-29. The single number that matters is whether FY2026 adjusted EBITDA lands inside the reconfirmed $62 to $72 million range, 13% to 31% growth over fiscal 2025. The third quarter set the momentum markers to check: record net revenue of $206.7 million with 11% organic growth, record international cannabis revenue, and the first impairment-free quarter of the new era. A clean fourth quarter would complete the first fiscal year in several without a major write-down.

The capital-structure calendar runs alongside. The 5.20% convertible notes mature June 15, 2027, and the company has been chipping at them through private debt-for-equity exchanges, including 2,638,341 shares issued for $12 million of principal between June 15 and 24, 2026; further exchanges or ATM draws under the $180 million program are the dilution events to track against a $497 million market value. On the regulatory front, the cannabis policy backdrop, US rescheduling developments and European medical-market expansion, remains the sector's swing factor, and Tilray's international cannabis line, which the FY2025 10-K shows growing 19% constant-currency, is the segment most directly geared to it. Sector sentiment has historically moved this stock more than fundamentals in the short run; the late-July print is the next chance for the fundamentals to argue back.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• INSP (Inspire Medical Systems, Inc.)
• FY2025 10-K: …• dedicated practice development; and • more effective clinical training teams. Most of the other OSA treatments against which we compete have a greater penetration into the OSA treatment market. Oral appliances and other surgical treatments are better known to ENT physicians, sleep centers, and the other physicians…
• FY2025 10-K: …gross margin has been and we expect it will continue to be affected by a variety of factors, including manufacturing costs, the average selling price of our Inspire system, the implementation of cost-reduction strategies, inventory obsolescence costs, which generally occur when new generations of our Inspire system…
• IONS (IONIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …may not be available or adequate in either the U.S. or international markets, which would negatively affect the potential commercial success of our products, our revenue and our profits. If we or our partners fail to compete effectively, our medicines, including our commercial medicines and our medicines in…
• FY2025 10-K: …regarding medicines that compete or may compete directly with our marketed medicines and late-stage medicines, refer to the section titled, Competition , in Part I, Item 1, Business . Certain of our partners are pursuing other technologies or developing other medicines either on their own or in collaboration with…
• NEOG (Neogen Corporation)
• FY2025 10-K: …economically feasible to do so. There can be no assurance that we would avoid a disruption of supply in the event a supplier discontinues shipment of product. Shipments of higher volume products are generally accomplished within a 48-hour turnaround time. COMPETITION While competitors differ across individual…
• FY2025 10-K: …higher level of customer insourcing that offset growth in the bovine market, paired with lower sales of insect control and veterinary instruments products lines which offset strength in sale of rodent control products. Operating Income Operating income for the Food Safety segment decreased $1,068.1 million during…
• PTCT (PTC Therapeutics, Inc.)
• FY2025 10-K: …considerations see "Item 1. Business-Government Regulation-Pharmaceutical Pricing and Reimbursement" and "Item 1A. Risk Factors-Risks Related to the Development and Commercialization of our Products and our Product Candidates" and "-Risks Related to Regulatory Approval of our Products and our Product Candidates".…
• FY2025 10-K: …how to allocate resources and in assessing performance. The Company's CODM consists of the chief executive officer, the chief financial officer, and the chief business officer. The Company views its operations and manages its business in one operating and reporting segment: life science. The life science segment is…
• TNDM (Tandem Diabetes Care, Inc.)
• FY2025 10-K: …customer service and clinical resources; • greater ability to respond to competitive pressures, regulatory uncertainty, or challenges within the financial markets; • established relationships with healthcare providers, third-party payors and regulatory agencies; • established reputation and name recognition among…
• FY2025 10-K: …rates with third-party payors. If third-party payors deny coverage or reduce their current levels of payment, or if our production costs increase faster than increases in reimbursement levels, we may be unable to sell our products on a profitable basis. 20 We operate in a very competitive industry and if we fail to…
• PBH (PRESTIGE CONSUMER HEALTHCARE INC.)
• FY2025 10-K: , or 8.1%, during 2025 versus 2024. As a percentage of International OTC Healthcare revenues, gross profit increased to 58.1% during 2025 from 57.2% during 2024, primarily due to an increase in revenue and product mix. Contribution Margin Contribution margin is our segment measure of profitability. It is defined as…
• FY2025 10-K: …was primarily attributable to an increase in sales in the Gastrointestinal category, partly offset by a decrease in sales in the Cough & Cold category. International OTC Healthcare Segment Revenues for the International OTC Healthcare segment increased $10.7 million, or 6.4%, during 2025 versus 2024. The $10.7…
• ACAD (ACADIA PHARMACEUTICALS INC)
• FY2025 10-K: …performance as the source for determining the Company's reportable segments. The Company determines and presents operating segments based on the information that is internally provided to the CEO who is considered the Company's CODM, in accordance with ASC 280, Segment Reporting . The Company has determined that it…
• FY2025 10-K: …to obtain or maintain favorable pricing and reimbursement status for any product candidates, if approved. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated…
• TCNNF (TRULIEVE CANNABIS CORP.)
• FY2025 10-K: …to respond to such increased demand. To remain competitive, we will require a continued investment in research and development, marketing, sales and client support. We may not have sufficient resources to maintain sufficient levels of investment in research and development, marketing, sales and client support efforts…
• FY2025 10-K: …judges in multiple states have on a number of occasions refused to enforce contracts for the repayment of money when the loan was used in connection with activities that violate U.S. federal law, even if there is no violation of state law. There remains doubt and uncertainty that we will be able to legally enforce…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.